Genscript Biotech Corp (OP:GNNSF)

1.840 UNCHANGED

Last Price Updated: 1:44 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genscript Biotech Corp

Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation? ↗

August 01, 2024

Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its...

Via Benzinga

Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal ↗

July 20, 2024

In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal.

Via Talk Markets

Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million ↗

June 08, 2024

Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...

Via Talk Markets

3 DNA Stocks to Buy for the Synthetic Biology Revolution ↗

May 14, 2023

Synthetic biology is a growing industry. The big winners will be DNA stocks that are able to sell to everyone, not just a small niche.

Via InvestorPlace

The Next Big Disruptors? 3 Biotech Stocks Making Headlines. ↗

February 17, 2023

Biotech stocks were hard-hit in 2022, but these disruptive names in the field of synthetic biology can be big winners in 2023.

Via InvestorPlace

Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million ↗

January 21, 2023

Mabwell Biosciences out-licensed global rights for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Mabwell will receive $10 million upfront, $402.5 million in...

Via Talk Markets

Three Pharma Stocks to Sell Before They Die ↗

December 24, 2022

As we head into New Year 2023, these are just some of the top pharma stocks to sell at the start of January.

Via InvestorPlace

Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact ↗

December 10, 2022

In a blockbuster agreement, Guangzhou’s Akeso out-licensed ex-China rights to its bispecific PD-1/VEGF candidate in a deal worth up to $5 billion. Summit Therapeutics will pay $500 million upfront and...

Via Talk Markets

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Genscript Biotech Corp (OP:GNNSF)

All News about Genscript Biotech Corp

Starting at $3.75/week.

Subscribe Today